Clinical Trial Update: Upfront Ruxolitinib for Chronic Graft-vs-host Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating upfront ruxolitinib for chronic graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Chronic Graft Versus Host Disease | Phase 1 | Status: TERMINATED